A Phase 4, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Tezepelumab in Patients With Severe Asthma, Including Underrepresented Racial and Clinical Groups: Initial Baseline Demographics and Clinical Characteristics From the PASSAGE Study

被引：0
|
作者：
Lugogo, N. L. [1 ]
Sumino, K. [2 ]
Akuthota, P. [3 ]
Burnette, A. F. [4 ]
Mathur, S. K. [5 ]
Lindsley, A. W. [6 ]
Llanos, J. [7 ]
Marchese, C. [8 ]
Cook, B. [9 ]
Martin, N. [10 ]
Ambrose, C. S. [9 ]
Emmanuel, B. [9 ]
机构：
[1] Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
[2] Washington Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA
[3] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92093 USA
[4] Howard Univ, Div Allergy & Immunol, Washington, DC 20059 USA
[5] Univ Wisconsin, Dept Med, Div Allergy Pulm & Crit Care Med, Madison, WI USA
[6] Amgen Inc, US Med Affairs, Thousand Oaks, CA USA
[7] Amgen Inc, Global Med Affairs, Thousand Oaks, CA USA
[8] AstraZeneca, BioPharmaceut R&D, Resp & Immunol, Late Stage Dev, Gothenburg, Sweden
[9] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Gaithersburg, MD USA
[10] AstraZeneca, BioPharmaceut Med, Resp & Immunol, Cambridge, England
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5374
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PASSAGE: A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF TEZEPELUMAB IN PATIENTS WITH SEVERE ASTHMA, INCLUDING UNDER-REPRESENTED GROUPS
    Lugogo, Njira L.
    Akuthota, Praveen
    Mathur, Sameer K.
    Burnette, Autumn
    Sumino, Kaharu
    Arya, Nikita
    Clarke, Nicole
    Lindsley, Andrew W.
    Ackert, Jean-Pierre Llanos
    Ambrose, Christopher
    Cook, William
    Emmanuel, Benjamin
    CHEST, 2022, 162 (04) : 37A - 40A
  • [2] A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)
    Zhang, Fengkui
    Peng, Guangxin
    He, Guangsheng
    Chang, Hong
    Gao, Sujun
    Liu, Xinjian
    Chen, Tong
    Li, Pei
    Han, Bing
    Miao, Miao
    Ge, Zheng
    Ge, Xiaoyan
    Li, Fei
    Li, Yingmei
    Wang, Shunqing
    Wang, Yi
    Shen, Yaqi
    Tai, Yanfei
    Zhang, Tao
    Zhu, Bo
    Zou, Jianjun
    BLOOD, 2020, 136
  • [3] Baseline Characteristics of the ENSEMBLE Study Population: A Phase IIIb Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
    Carroll, W.
    Brochet, B.
    Patti, F.
    Buffels, R.
    Wei, W.
    Vollmer, T.
    Hartung, H. P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 475 - 475
  • [4] Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study
    Tsai, T. F.
    Liu, M. T.
    Liao, Y. H.
    Licu, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (03) : 345 - 352
  • [5] Baseline Demographics Of The Prospective, Multicenter, Single-Arm, Open-Label, Phase Iv Motion Study Of Riociguat In Pulmonary Arterial Hypertension
    Sood, N.
    Aranda, A.
    Mobin, S.
    Platt, D.
    O'Brien, G.
    Satler, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [6] Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study
    Onodera, Masafumi
    Uchiyama, Toru
    Ariga, Tadashi
    Yamada, Masafumi
    Miyamura, Takako
    Arizono, Hironori
    Morio, Tomohiro
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (07)
  • [7] A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis
    Vuppalanchi, Raj
    Gonzalez-Huezo, Ma Sarai
    Payan-Olivas, Ramon
    Munoz-Espinosa, Linda E.
    Shaikh, Farheen
    Cruz-Lopez, Jose L. Pio
    Parmar, Deven
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (04) : E00327
  • [8] Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial
    Williams, Mitzi J.
    Okai, Annette F.
    Cross, Anne H.
    Monson, Nancy L.
    Vartanian, Timothy
    Thrower, Ben W.
    Reder, Anthony T.
    English, Jeffrey B.
    Wu, Gregory F.
    Bernitsas, Evanthia
    Yap, Shereen
    Ndrio, Jugena
    Pei, Jinglan
    Mowry, Ellen M.
    Magrini, Fabio
    Acosta, Juan
    Amezcua, Lilyana
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 76
  • [9] Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study
    Huang, P. H.
    Liao, Y. H.
    Wei, C. C.
    Tseng, Y. H.
    Ho, J. C.
    Tsai, T. F.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (08) : 923 - 930
  • [10] Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
    Shuichi Ito
    Yuya Nishiyama
    Kenkichi Sugiura
    Kazuaki Enya
    Clinical and Experimental Nephrology, 2022, 26 : 350 - 358
12345